NMR Quantification of TMAO
A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosample may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 μM or urine with a normal biologic range of between about 0-1000 μM.
1 . A method of determining a measure of TMAO in in vitro biosamples, comprising:
generating a proton NMR spectrum for an in vitro biosample; and
electronically determining a level of trimethylamine-N-oxide (“TMAO”) in the in vitro biosample using a defined TMAO peak region having a single TMAO peak residing between about 3.2 and 3.4 ppm of the proton NMR spectrum.
2 . The method of claim 1 , further comprising:
electronically calculating a distance between the reference and calibration peak regions; and
electronically determining a location of the TMAO peak for the defined TMAO peak region based on the calculated distance.
3 . The method of claim 2 , wherein the electronically determining the TMAO peak region location is carried out using a defined relationship of location of the reference peak region to location of the calibration peak region.
4 . The method of claim 1 , wherein the biosample is a blood plasma or serum wherein the defined TMAO peak is at about 3.30 ppm.
5 . The method of claim 1 , further comprising:
electronically identifying a defined calibration peak multiplet with peaks that can vary in distance apart from one another based on pH of the biosample;
determining at least one distance between one or more of the peaks in the calibration peak multiplet; and
electronically determining a pH of the biosample based on the at least one determined distance;
wherein the electronically determining the location of the TMAO peak for the defined TMAO peak region is carried out based on the determined pH and/or the at least one distance between peaks in the calibration multiplet.
6 . The method of claim 1 , further comprising, before the electronically determining step, electronically calculating a location of the defined TMAO peak region using a fitting region having a size between about 50-100 data points based on a location of a citrate reference peak or peaks, then reducing the fitting region to about 30 data points centered about the calculated location of the defined TMAO peak region, and electronically curve fitting the defined TMAO peak region with a defined curve fitting function or functions to determine the level of TMAO.
7 . The method of claim 1 , wherein the electronic determination of the level of TMAO is carried out using a defined relationship between a location of a reference peak or peaks and a location of a pH sensitive calibration peak or peaks, and an expected TMAO peak location, wherein a probable actual TMAO peak location is then identified by:
electronically weighting a region around the expected TMAO peak location with a defined function; then
electronically identifying a highest weighted data point of the weighted region; then
electronically identifying a probable actual TMAO peak location corresponding to location of the highest weighted data point.
8 . (canceled)
9 . The method of claim 7 , wherein after the identification of the probable actual TMAO peak location, the method further comprises applying a curve fitting function or functions to a curve fitting region of about 30 to about 50 data points centered about the identified probable actual TMAO peak location to determine the level of TMAO.
10 . The method of claim 7 , wherein the curve fitting function or functions can selectively allow for one or more neighbors on either side of the probable actual TMAO peak location to account for misalignments to determine the level of TMAO.
11 - 22 . (canceled)
23 . A processor configured to evaluate in vitro biosamples, the processor configured to
generate a proton NMR spectrum for an in vitro biosample; and
electronically determine NMR signal in at least one defined peak region that includes a trimethylamine-N-oxide (TMAO) peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample to determine a level of TMAO.
24 - 53 . (canceled)
54 . A system comprising the processor of claim 23 and an NMR spectrometer for acquiring a proton NMR spectrum of an in vitro biosample.
55 . A method of monitoring patients for therapeutic treatment, comprising:
electronically determining a level of trimethylamine-N-oxide (“TMAO”) in an in vitro biosample from the subject using a defined TMAO peak region having a single TMAO peak residing between about 3.2 and 3.4 ppm of a proton NMR spectrum; and
administering a prebiotic, probiotic, or drug to the patient based on the level of TMAO in the biosample.